ANPCY

More ANPCY headlines

20 articles

CelLBxHealth PLC Presents Proof-of-Concept Study

accessnewswire.com·Nov 5

Cellbxhealth PLC Announces Expert Consensus on CTCs; Update on Funding

accessnewswire.com·Nov 4

ANGLE plc Announces Appointments: Interim CEO and Senior Board Advisor

accessnewswire.com·Oct 16

Angle PLC Announces Strategy Update

accessnewswire.com·Oct 8

Angle PLC Announces Presentation of Data on Glioblastoma

accessnewswire.com·Sep 29

Angle PLC Announces Notice of Results

accessnewswire.com·Sep 5

ANGLE Announces Collaboration with Myriad Genetics

accessnewswire.com·Aug 20

Angle PLC Announces Parsortix Enables Study Of Cancer Progression

accessnewswire.com·Jul 8

ANGLE PLC Announces Result of 2025 Annual General Meeting

accessnewswire.com·Jun 30

Angle PLC - EACR 2025: Data Demonstrating DNA Dual Analysis

accessnewswire.com·Jun 17

Angle PLC - EACR 2025: Innovation in AR Expression Profiling

accessnewswire.com·Jun 17

ANGLE plc Announces Novel Discoveries Into the Biology of Cancer

accessnewswire.com·Jun 10

Angle PLC Announces Posting of Annual Report and Notice of AGM

accessnewswire.com·Jun 9

Angle PLC Announces Board Changes

accessnewswire.com·Jun 6

Angle PLC Announces Preliminary Results

accessnewswire.com·May 28

Angle PLC Announces Notice of Results

accessnewswire.com·May 23

Angle PLC Announces Results of Eisai Phase 2 pilot study

accessnewswire.com·Mar 21

Angle PLC Announces Issue of LTIP Options and Share Options

accessnewswire.com·Mar 21

Angle PLC Announces Analysis of CTC-DNA and ctDNA using Illumina assay

accessnewswire.com·Jan 29

Angle PLC Announces Parsortix Used in Research Paper from ETH Zurich

accessnewswire.com·Jan 24
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.